Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?

Amneal Pharmaceuticals AMRX completed its acquisition of Kashiv BioSciences on Monday, creating an integrated global biosimilars platform spanning research, development, manufacturing and commercialization.

The deal broadens Amneal's biosimilar capabilities as it seeks more consistent launches. The investment case still depends on integration, regulatory execution and product uptake.

Amneal Gains an End-to-End Biosimilar Platform

Kashiv adds development and manufacturing capabilities to Amneal's existing commercialization platform. Bringing those functions together is intended to support a steadier biosimilar launch cadence and advance the combined pipeline.

Management has positioned biosimilars as a major long-term growth pillar. Affordable Medicines already includes injectables and biosimilars across multiple dosage forms, so Kashiv expands an established operating area and adds another growth avenue.

AMRX Targets a Large Biologics Opportunity

Amneal cites more than $300 billion of projected global biologics loss-of-exclusivity opportunities over the next decade. The Kashiv transaction is designed to position the company to pursue that market with a broader, integrated platform.

Competition is active. Teva Pharmaceutical Industries TEVA said in July that it was expanding its biosimilars portfolio through the European launch of Ahzantive and a collaboration on a proposed biosimilar to Ocrevus.

Alvotech ALVO is also advancing multiple candidates. In June, it resubmitted U.S. biologics license applications for proposed biosimilars to Simponi and Simponi Aria, as well as Eylea, underscoring the development pace in this market.

Amneal Can Pair the Deal With Existing Launches

Amneal is not starting from scratch. A biosimilar to Novartis' Xolair remains under review, with a potential launch expected by the end of 2026 if approved.

Approval of that product would bring Amneal's U.S. biosimilar portfolio to six products. Amneal expects 20 to 30 new Affordable Medicines launches each year, with complex products playing an important role in that broader cadence.

AMRX Still Needs Smooth Integration and Approvals

The growth opportunity comes with execution risk. Amneal must integrate Kashiv's development and manufacturing operations while continuing to advance the biosimilar pipeline and meet demanding regulatory and production requirements.

Approval delays, complete response letters or slower-than-expected market adoption could weigh on growth projections. Complex products, including biosimilars, face greater development complexity, stricter manufacturing requirements and rigorous FDA scrutiny.

Amneal's Broader Mix Could Improve Over Time

Biosimilars add another growth avenue alongside complex generics, specialty medicines and injectables. Total net revenues were $3.0 billion in fiscal 2025, up 8% year over year. Affordable Medicines contributed $1.7 billion, or 57.8% of total revenues, while Specialty contributed $528.5 million, or 17.5%. Amneal's broader portfolio includes approximately 300 complex, specialty and biosimilar medicines.

AvKARE contributed another $744.7 million, or 24.7% of fiscal 2025 revenues. Adding an integrated biosimilar platform broadens that diversified base as Amneal works to advance the combined pipeline and support future launches.

AMRX's Biosimilar Thesis Gets a Strong Near-Term Signal

The bottom line is that Kashiv expands Amneal's biosimilar capabilities at a time when the company is targeting a sizable biologics loss-of-exclusivity opportunity. The platform broadens the runway, but integration and regulatory execution remain central to realizing that potential.

AMRX carries a Zacks Rank #1 (Strong Buy), reflecting a favorable near-term earnings-estimate revision signal. The stock also has a Value Score of B, but its Growth Score of F, Momentum Score of D and VGM Score of D show weaker support across other investment styles.

You can see the complete list of today’s Zacks #1 Rank stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research